Mallinckrodt's medical sales grow 4%
This article was originally published in Clinica
Executive Summary
Mallinckrodt Medical's revenues were up 4% to $1,055 million in the 12 months to the end of June. Major contributors to sales growth were anaesthetic and nuclear medicine products augmented by the January 1996 acquisition of Liebel-Flarsheim, a manufacturer of contrast media injection systems.